New Tufts CSDD shows decentralization accelerates clinical trials.

Clinical research passes an important milestone with the release of Tufts CSDD’s new report: Assessing the Value of Decentralized Clinical Trials (DCTs)

According to researchers Joseph A. DiMasi, Ken Getz, and Pamela Tenaerts, decreases in clinical trial cycle times, screen failure rates and substantive protocol elements help drive:

  • Phase II studies - Possible net benefits up to 5x greater than the upfront investment required.
  • Phase III studies - Possible net benefits up to 13x greater than the upfront investment required.

Download the research for free to learn more.

Heading

Heading

Heading

Save the Date!
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.